Cas:164648-64-0 4-(aminomethyl)-2-methylbenzamide manufacturer & supplier

Chemical Name:4-(aminomethyl)-2-methylbenzamide

CAS.NO:164648-64-0

Synonyms:4-(aminomethyl)-2-methylbenzamide

Molecular Formula:C₉H₁₂N₂O

Molecular Weight:164.20400

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:55.12000

Exact Mass:164.09500

LogP:1.59610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(aminomethyl)-2-methylbenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(aminomethyl)-2-methylbenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(aminomethyl)-2-methylbenzamide Use and application,4-(aminomethyl)-2-methylbenzamide technical grade,usp/ep/jp grade.

Related News: Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 4-(aminomethyl)-2-methylbenzamide manufacturer The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term. 4-(aminomethyl)-2-methylbenzamide supplier First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 4-(aminomethyl)-2-methylbenzamide vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 4-(aminomethyl)-2-methylbenzamide factory The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.